Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
Serapha Bio named Kenneth T. Mills as CEO and board member and appointed a full senior leadership team, including Daphne Karydas as President and CFO, Weston Miller as CMO, Nina Hunter as Chief Development Officer and Shiva Fritsch as Chief Corporate Affairs Officer. The company reaffirmed that its merger with Boundless Bio (Nasdaq: BOLD) remains on track to close in Q4 2026, supported by roughly $230 million in committed pre-closing private investments co-led by RTW Investments and RA Capital, with about $138 million already funded and approximately $92 million more expected at closing. The combined company will trade on Nasdaq under the ticker AATD, subject to approval.
Key figures
- Drug Name
- SERP-01
- Phase Of Trial
- Phase 2/3
- Post merger ticker
- AATD
- Series a funded usd
- 138000000
- Expected merger close
- Q4 2026
- Regulatory designations
- ["orphan drug designation","RMAT designation","IND clearance"]
- Phase23 initiation window
- late 2026 or early 2027
- Pre closing private investments usd
- 230000000
- Expected funding at merger close usd
- 92000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.